Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Anat Stemmer-Rachamimov, M.D.

Co-Author

This page shows the publications co-authored by Anat Stemmer-Rachamimov and Rakesh Jain.
Connection Strength

0.400
  1. Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. Neuro Oncol. 2013 Aug; 15(8):1079-87.
    View in: PubMed
    Score: 0.136
  2. Losartan prevents tumor-induced hearing loss and augments radiation efficacy in NF2 schwannoma rodent models. Sci Transl Med. 2021 07 14; 13(602).
    View in: PubMed
    Score: 0.059
  3. A Glial Signature and Wnt7 Signaling Regulate Glioma-Vascular Interactions and Tumor Microenvironment. Cancer Cell. 2018 05 14; 33(5):874-889.e7.
    View in: PubMed
    Score: 0.047
  4. Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models. Proc Natl Acad Sci U S A. 2018 02 27; 115(9):E2077-E2084.
    View in: PubMed
    Score: 0.047
  5. Anti-VEGF treatment improves neurological function in tumors of the nervous system. Exp Neurol. 2018 01; 299(Pt B):326-333.
    View in: PubMed
    Score: 0.045
  6. Anti-VEGF treatment improves neurological function and augments radiation response in NF2 schwannoma model. Proc Natl Acad Sci U S A. 2015 Nov 24; 112(47):14676-81.
    View in: PubMed
    Score: 0.040
  7. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med. 2009 Jul 23; 361(4):358-67.
    View in: PubMed
    Score: 0.026
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.